A nursing instructor is teaching about pharmacological treatments for attention deficit-hyperactivity disorder (ADHD). Which information about atomoxetine (Strattera) should be included in the lesson plan?

A. Strattera will be a life-long intervention for clients diagnosed with this disorder: Atomoxetine may be used long-term, but treatment duration varies based on symptom control and individual response. It is not automatically a life-long intervention for all clients. B. Strattera, unlike methylphenidate (Ritalin), is a selective norepinephrine reuptake inhibitor: Atomoxetine works by selectively inhibiting the reuptake of norepinephrine, improving attention and reducing hyperactivity and impulsivity. This mechanism differs from stimulant medications like methylphenidate, which increase dopamine and norepinephrine activity in the central nervous system. C. When taking Strattera, a client should not be taking Ritalin or any other stimulant: While caution is advised when combining medications, atomoxetine can be used under medical supervision with other agents if clinically indicated. Absolute avoidance is not universally required. D. Strattera, unlike methylphenidate (Ritalin), is a central nervous system depressant: Atomoxetine is not a CNS depressant; it is a non-stimulant ADHD medication that increases norepinephrine levels. It does not have sedative or depressant effects on the central nervous system.